Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

213 results about "Natural killer cell" patented technology

Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.

CD83-binding chimeric antigen receptors

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Method of treating alzheimer's disease with expanded natural killer cells

A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Owner:NKMAX CO LTD

Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Owner:NOVARTIS AG +1

Lung-targeted exosome complex as well as preparation method and application thereof

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.
Owner:BEIJING INST OF TECH

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Composition for enhancing immunity comprising polysaccharide enzyme-treated product or purified fraction thereof

PCT designated stageWO2026135372A1Food shapingBiotechnologyAngelica gigas
The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.
Owner:KOLMAR BNH CO LTD

NK cell and application thereof in tumor treatment medicine

The invention belongs to the technical field of tumor immunotherapy, and relates to an anti-Claudin18.2 single-domain antibody, a multifunctional fusion protein, a recombinant natural killer cell (CT-CAR-NK), and preparation and application thereof. Through alpaca immunization and phage display library construction and panning, the single-domain antibody VHH-C18.2-1 specifically combined with Claudin18.2 is obtained, and the amino acid sequence of the single-domain antibody VHH-C18.2-1 is SEQ ID NO: 1. The amino acid sequence of the designed fusion protein is SEQ ID NO: 3, the fusion protein sequentially comprises a VHH-C18.2-1, a flexible Linker, a TGF-beta RII extracellular domain, a CD8alpha hinge region, a CD8alpha transmembrane region, a 4-1BB intracellular domain and a CD3zeta intracellular domain from the N end to the C end, and the fusion protein has the functions of targeting, resisting TGF-beta inhibition and activating signals. The fusion protein gene transfects human peripheral blood CD56 + CD3-NK cells through lentivirus to obtain CT-CAR-NK, in-vitro verification shows that the CT-CAR-NK still keeps efficient killing in an immunosuppression environment, tumor growth can be remarkably inhibited in vivo, the lifetime can be prolonged, and a safe and efficient scheme is provided for Claudin18.2 positive solid tumor treatment.
Owner:GUANGDONG ZHILUO BIOTECHNOLOGY CO LTD

CD19 and CD22 chimeric antigen receptors and uses thereof

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.
Owner:NOVARTIS AG

Inhibitory chimeric antigen receptor and uses thereof

We provide compositions and methods to enhance the anti-cancer specificity of chimeric antigen receptor natural killer cells (CAR-NK) by activating them against cancer antigens while inhibiting them against human leukocyte antigen DR (HLA-DR). HLA-DR is reportedly lost or downregulated in a substantial proportion of hematologic malignancies. An anti-HLA-DR inhibitory CAR (iCAR) is provided to effectively suppress NK cell activation against HLA-DR-expressing cells. Dual CAR-NK cells, which co-express the anti-CD19 or anti-CD33 activating CAR and the anti-HLA-DR iCAR, can preferentially target HLA-DR-negative cells over HLA-DR-positive cells in vitro. The HLA-DR-mediated inhibition is positively correlated with both iCAR and HLA-DR densities. Surrounding cells that express HLA-DR do not affect the target selectivity of the dual CAR-NK cells. We have confirmed that HLA-DR-positive cells are resistant to dual CAR-NK cell-mediated killing in a xenograft mouse model. This can be used for enhancing CAR-NK and CAR-T cell specificity against malignancies with HLA-DR loss.
Owner:UNIV OF SOUTHERN CALIFORNIA

Engineered bispecific exosome preparation with tumor targeted breakthrough capability as well as preparation method and application of engineered bispecific exosome preparation

The invention discloses an engineered exosome preparation with tumor targeting and specific gripper response release functions as well as a preparation method and application of the engineered exosome preparation. The preparation comprises a myocardial cell exosome, an NK cell biotinylation activation antibody, a tumor disease biotinylation antibody, streptavidin, a tumor fiber matrix FAP targeting peptide and a tumor matrix enzyme response peptide, and anchoring is carried out through an acetamide compound-polyethylene glycol anchor point platform. The engineering bispecific exosome preparation with good tumor targeting and barrier breakthrough ability and immune cell activation effect is prepared, and the preparation breaks a solid tumor compact fiber barrier and increases NK cell infiltration by utilizing the fibrosis treatment ability of the myocardial cell exosome and the capture and targeting effects of an anchor point platform; the natural killer cells are in close contact with tumor cells, the lasting tumor cell killing effect is achieved, and the tumor matrix environment is fundamentally changed.
Owner:CHINA PHARM UNIV

Chimeric protein of IL-2 protein and IL-15 protein or variant thereof, fusion protein containing the protein, and genetically engineered cell expressing the protein

The present invention relates to a chimeric protein of IL-2 protein and IL-15 protein, a variant thereof, a fusion protein comprising the same, and / or a genetically engineered cell modified to express any one or more thereof. In the present invention, the binding to IL-2Rβ is weakened, the side effects caused by the excessive immune cell activity of IL-2 can be inhibited, and the rapid exhaustion of natural killer cells is prevented, thereby allowing the appropriate level of cell activity and cell survival ability to be maintained for a long time. Accordingly, the present invention can be used for modulating the immune system and treating immune-related diseases, such as cancer, infectious diseases, and autoimmune diseases.
Owner:GI CELL INC

Multispecific antigen-binding protein with improved expression efficiency

PCT designated stageWO2026142367A1Heavy chainBispecific antibody
The present invention relates to a nucleic acid molecule encoding a multispecific antigen-binding protein and exhibiting significantly improved expression efficiency in vivo. In the multispecific antigen-binding protein of the present invention, specifically, a bispecific antibody that recognizes a tumor antigen or a viral antigen and a natural killer cell-specific activating receptor, the light chain variable region (VL) and the heavy chain variable region (VH) of a receptor-recognizing site of a natural killer cell-specific activating receptor are sequentially arranged in the N-terminus to the C-terminus direction, thereby increasing expression efficiency by up to 8-fold. Therefore, the present invention provides an optimal mRNA structure capable of most efficiently expressing bispecific antibodies in vitro and in vivo, thereby enabling effective use thereof for not only mass-production of recombinant bispecific antibodies but also as an excellent mRNA therapeutic agent for stable and continuous production of a therapeutically effective amount of bispecific antibodies in the body of a patient.
Owner:DE NOVO BIOTHERAPEUTICS CO LTD

Compositions and methods of NKG2D chimeric antigen receptor T cells for controlling triple-negative breast cancer

The invention includes a chimeric antigen receptor (CAR) specific for a natural-killer group 2, member D ligand (NKG2DL), compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising a polynucleotide encoding the CAR, and recombinant T cells comprising the CAR. The invention also includes methods of making a genetically modified T cell expressing a NKG2D-CAR wherein the expressed CAR comprises a NKG2D extracellular domain. The present invention also relates generally to the use of T cells engineered to express a CAR to treat cancer associated with NKG2D.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Natural killer cells expressing a chimeric antigen receptor that binds CD38

Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.
Owner:ONK THERAPEUTICS LTD

Method for large-scale expansion of natural killer (NK) cells in cell culture medium

A method for large-scale expansion of natural killer (NK) cells in a cell culture medium according to the invention, comprising the steps of: adding said cells to a culture system comprising a growth medium supplemented with serum selected from the group consisting of human serum and autologous plasma; cRX 527 with an effective concentration is added; the cells are expanded and heated within the system wherein the effective concentration of CRX 527 in the growth medium is in the range of 0.01 [mu] g / ml to 10 [mu] g / ml, preferably 100 ng / ml, and the ratio between the cell density and the total volume of the growth medium is in the range of 1.5 to 2.
Owner:MEIZE ASSET MANAGEMENT CO LTD

Transduction and expansion of cells

Provided is a method of transducing and expanding a population of cells, the method comprising, in order: a cell selection step; a pre-transduction activation step; a cell transduction step; and a cell expansion phase. At least the cell transduction step and the expansion phase comprise incubation of the cells with IL-15. The methods of the invention are well suited to the transduction and expansion of populations of cells expressing chimeric antigen receptors (CARs), and in particular for the transduction and expansion of populations of invariant natural killer T (iNKT) cells expressing CARs. Also provided are populations of cells produced by the methods of the invention, and pharmaceutical compositions comprising populations of cells, as well medical uses of the pharmaceutical compositions and populations of cells. The cells and pharmaceutical composition are suitable for application in medical use and methods of treatment, including immunotherapy.
Owner:IMPERIAL COLLEGE INNVOATIONS LTD

NK cell delivery data processing method and system based on magnetic targeting

The invention relates to the technical field of medical engineering, in particular to an NK cell delivery data processing method and system based on magnetic targeting. The method comprises the following steps: inquiring an immune receptor protein structure of natural killer cells; injecting a sodium chloride solution, adding an immune receptor protein structure, and reacting to generate an aptamer structure; the method comprises the following steps: combining streptavidin in a pre-prepared glycosyl magnetic microsphere to obtain a high-affinity magnetic bead; carrying out molecular docking on the high-affinity magnetic beads and the aptamer structure, recording a docking score, and generating an optimized aptamer; recording the magnetic bead mass ratio of the optimized aptamer; capturing the natural killer cells by adopting the optimized aptamer, and shooting to obtain a fluorescent microscopic image; and recording the dyeing condition of the fluorescent microscopic image, determining the survival state of the NK cells, marking the position information of the living cells, and generating an NK cell delivery efficiency table by using the mass ratio of the magnetic beads. Based on a medical engineering technology, the homing rate and the delivery efficiency of the NK cells at the liver injury part are improved.
Owner:FIRST HOSPITAL OF QINHUANGDAO +1

Membrane-anchored NK cell inhibitory receptor engagers

Some aspects relate to engineered cells expressing synthetic natural killer (NK) cell inhibitory receptor (e.g., CD161, NKG2A) engagers. Some aspects relate to methods of producing engineered cells expressing a synthetic NK cell inhibitory receptor engager. Some aspects relate to uses of cells expressing synthetic NK cell inhibitory receptor engagers.
Owner:GENTIBIO INC

Methods of Manufacturing Therapeutic Cells

Provided are methods of manufacturing cells. The methods comprise expanding cells in the presence of inosine, and harvesting the cells after expansion. In certain embodiments, the cells are genetically modified. For example, the cells may be genetically modified to express an engineered receptor, non-limiting examples of which are chimeric antigen receptors (CARs), engineered T cell receptors (TCRs), and the like. According to some embodiments, the cells are immune cells, e.g., T cells or natural killer cells. Also provided are populations of cells manufactured according to the methods of the present disclosure. Also provided are methods comprising administering an effective amount of a population of cells manufactured according to the methods of the present disclosure to a subject in need thereof. In certain embodiments, the subject has cancer, and the cells express an engineered receptor that binds to a tumor antigen on the surface of cells of the cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

NK cells or T cells expressing chimeric hematopoietic growth factor receptor and their usage

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

A combination drug for preventing and / or treating prostate cancer, use thereof, and a pharmaceutical composition

The present application belongs to the field of chemical medicine, and particularly relates to a combined drug for preventing and / or treating prostate cancer, use and pharmaceutical composition thereof. The combined drug of the present application is an immune cell with enhanced infiltration degree and a galectin-1 inhibitor; the immune cell with enhanced infiltration degree is a natural killer (NK) cell with TTTY15-USP9Y chimera RNA knocked out, which can increase the infiltration degree and anti-tumor activity of the NK cell in the prostate cancer microenvironment, and the activated NK cell has stronger killing effect on tumor cells in vitro. The present application combines the immune cell with enhanced infiltration degree and the galectin-1 inhibitor, and the combination shows synergistic effect in treating prostate cancer, and has wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

SSTR-binding antibodies and chimeric antigen receptors

Disclosed are compositions and methods for targeted treatment of SSTR-expressing cancers. For example, disclosed herein are Bispecific T-Cell Engaging (BiTE) molecules (fusion polypeptides) (also referred to herein as bispecific molecules) that are able to crosslink CD3 complex on immune effector cells with SSTR2 on NETs. Also disclosed are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill SSTR-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a SSTR-expressing cancer, such as a neuroendocrine tumor, that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Use of a kat5 inhibitor in enhancing the efficacy of natural killer cell immunotherapy drugs, drugs

The application belongs to the technical field of biological medicine, and particularly relates to application of a KAT5 inhibitor in a medicine for enhancing the immunotherapy effect of natural killer cells, and a medicine for enhancing the immunotherapy effect of natural killer cells. The KAT5 inhibitor comprises at least one of Nu9056, TH1834 and MG149. The KAT5 inhibitor can inhibit the recruitment of a transcription factor SP1 to an ADAM10 promoter, reduce the transcriptional activity of ADAM10, reduce the expression of NKG2D ligands on the cell surface, and thus enhance the sensitivity of tumor cells to NK cell killing. The application first discloses a new mechanism in which KAT5 regulates an ADAM10-NKG2D signal axis through an epigenetic mechanism, and proves that the KAT5 inhibitor can significantly enhance the immunotherapy effect of NK cells in vitro and in vivo. The application provides a brand-new target and strategy for developing a new immunosensitizer and a combined cell therapy.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Oligosaccharide selenium ganoderma lucidum capsule capable of enhancing immunity and inhibiting tumors and preparation method of oligosaccharide selenium ganoderma lucidum capsule

The invention belongs to the technical field of health-care products, and discloses an oligosaccharide selenium ganoderma lucidum capsule for enhancing immunity and inhibiting tumors and a preparation method, and the content of the capsule is prepared from the following raw materials in parts by mass: 150-160 parts of collagen, 80-85 parts of chitosan oligosaccharide, 110-130 parts of ganoderma lucidum extract, 45-55 parts of selenium-enriched yeast, 50-80 parts of maltodextrin and 7-10 parts of magnesium stearate. The skin barrier can be improved, intercellular communication can be promoted and local immune response can be stimulated through low-molecular peptide of collagen, intestinal flora balance can be adjusted through chitosan oligosaccharide, probiotic growth can be promoted, mucous membrane immunity can be further improved, and finally immune cells can be effectively activated through polysaccharide and triterpenoids in the ganoderma lucidum extract, so that the immunity of a human body is improved. The activity of macrophages and natural killer cells is enhanced, and the multi-target and multi-path immune regulation effect can effectively enhance the defense of the body to pathogenic microorganisms.
Owner:SHANDONG WEIKANG BIOMEDICAL TECH CO LTD

Drug resistant immune cells

Compositions and method of prevention and treatment for a subject in need comprising drug-resistant natural killer (NK) cells, which are effective for treating cancer when administered in conjunction with cytotoxic therapies. A method of treatment comprising administering to a subject in need thereof an effective amount of modified NK cells and a cytotoxic therapy. A purified cell composition comprising modified NK cells. A pharmaceutical composition comprising an effective amount of G101V mutated NK cells and venetoclax.
Owner:RGT UNIV OF CALIFORNIA